Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 27;7:14. doi: 10.1038/s41541-022-00432-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Dot plot to compare spike-specific cellular responses by IFN-γ ELISpot in participants who obtained the BNT162b2 vaccine with a standard interval of 3 weeks apart at bleed time point 1 (2–3 weeks post vaccine dose 2) and timepoint 2 (10–11 weeks post vaccine dose 2) (Wilcoxon matched-pairs signed rank test; p < 0.0001). b Dot plot to compare spike-specific antibody responses by IFN-γ ELISpot in participants who obtained the BNT162b2 vaccine with an extended interval at bleed timepoint 1 (5–6 weeks post vaccine dose 1) and timepoint 2 (2–3 weeks post vaccine dose 2) (Wilcoxon matched-pair signed-rank test). c The percentage of donors with a positive IFN-γ ELISpot T-cell response is shown in the two different vaccine-interval cohorts over a 14-week period. The percentage response of those donors receiving the vaccine doses on a standard interval are shown in blue, while those receiving it on an extended interval are shown in red. d Dot plot to compare spike-specific cellular responses by ELISpot in the participants 2–3 weeks after the second dose of BNT162b2 vaccination in the standard- and extended-interval cohorts (median and IQR shown) (Mann–Whitney U test, p < 0.0001).